Literature DB >> 18440205

Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions.

Christopher B Fox1, Ryan C Anderson, Timothy S Dutill, Yasuyuki Goto, Steven G Reed, Thomas S Vedvick.   

Abstract

Oil-in-water emulsions have shown promise as safe and effective adjuvant formulations for vaccines. In particular, formulations consisting of metabolizable oils such as shark-derived squalene and detergents such as egg phosphatidylcholine have been used to produce stable vaccine emulsion formulations. However, there is an emphasis in pharmaceutical regulatory bodies on using synthetic or plant-derived components from sustainable sources instead of animal-derived components. This study compares the physicochemical properties and biological efficacy of emulsions consisting of oil and detergent components from animal, plant, and synthetic sources. In particular, effects of component structure and source on emulsion stability and biological activity are examined. It is shown that oil-in-water emulsions using animal-derived components can be substituted with synthetic or plant-derived materials while still exhibiting satisfactory physicochemical and biological properties.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18440205     DOI: 10.1016/j.colsurfb.2008.03.003

Source DB:  PubMed          Journal:  Colloids Surf B Biointerfaces        ISSN: 0927-7765            Impact factor:   5.268


  19 in total

1.  GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults.

Authors:  Hayedeh Behzad; Anke L W Huckriede; Laura Haynes; Beth Gentleman; Krysta Coyle; Jan C Wilschut; Tobias R Kollmann; Steven G Reed; Janet E McElhaney
Journal:  J Infect Dis       Date:  2011-12-05       Impact factor: 5.226

Review 2.  Use of defined TLR ligands as adjuvants within human vaccines.

Authors:  Malcolm S Duthie; Hillarie Plessner Windish; Christopher B Fox; Steven G Reed
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

3.  Immunisation with ID83 fusion protein induces antigen-specific cell mediated and humoral immune responses in cattle.

Authors:  Gareth J Jones; Sabine Steinbach; Derek Clifford; Susan L Baldwin; Gregory C Ireton; Rhea N Coler; Steven G Reed; H Martin Vordermeier
Journal:  Vaccine       Date:  2013-09-05       Impact factor: 3.641

4.  Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization.

Authors:  Mark T Orr; Ryan M Kramer; Lucien Barnes; Quinton M Dowling; Anthony L Desbien; Elyse A Beebe; John D Laurance; Christopher B Fox; Steven G Reed; Rhea N Coler; Thomas S Vedvick
Journal:  J Control Release       Date:  2013-12-29       Impact factor: 9.776

5.  Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions.

Authors:  Christopher B Fox; Susan L Baldwin; Malcolm S Duthie; Steven G Reed; Thomas S Vedvick
Journal:  Vaccine       Date:  2011-09-09       Impact factor: 3.641

6.  Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions.

Authors:  Christopher B Fox; Susan L Baldwin; Malcolm S Duthie; Steven G Reed; Thomas S Vedvick
Journal:  AAPS PharmSciTech       Date:  2012-03-14       Impact factor: 3.246

7.  Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains.

Authors:  Janny Westdijk; Patrick Koedam; Mario Barro; Benjamin P Steil; Nicolas Collin; Thomas S Vedvick; Wilfried A M Bakker; Peter van der Ley; Gideon Kersten
Journal:  Vaccine       Date:  2013-01-09       Impact factor: 3.641

8.  Development and in vitro evaluation of a nanoemulsion for transcutaneous delivery.

Authors:  Grace Ledet; Sarala Pamujula; Valencia Walker; Shana Simon; Richard Graves; Tarun K Mandal
Journal:  Drug Dev Ind Pharm       Date:  2013-04-19       Impact factor: 3.225

9.  Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.

Authors:  Mark T Orr; Christopher B Fox; Susan L Baldwin; Sandra J Sivananthan; Elyse Lucas; Susan Lin; Tony Phan; James J Moon; Thomas S Vedvick; Steven G Reed; Rhea N Coler
Journal:  J Control Release       Date:  2013-08-09       Impact factor: 9.776

10.  Perioperative treatment with the new synthetic TLR-4 agonist GLA-SE reduces cancer metastasis without adverse effects.

Authors:  Pini Matzner; Liat Sorski; Lee Shaashua; Ely Elbaz; Hagar Lavon; Rivka Melamed; Ella Rosenne; Neta Gotlieb; Amit Benbenishty; Steve G Reed; Shamgar Ben-Eliyahu
Journal:  Int J Cancer       Date:  2015-10-26       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.